Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Daniel Bowles

Concepts (346)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
31
2026
2194
3.380
 Why?
Head and Neck Neoplasms
16
2023
558
2.860
 Why?
Salivary Gland Neoplasms
8
2023
39
2.830
 Why?
Protein Kinase Inhibitors
15
2026
969
2.240
 Why?
Carcinoma, Squamous Cell
14
2019
641
2.220
 Why?
Pyridines
14
2026
605
2.130
 Why?
Thyroid Neoplasms
9
2024
345
1.840
 Why?
Carcinoma, Non-Small-Cell Lung
9
2026
1180
1.710
 Why?
Molecular Targeted Therapy
7
2021
432
1.640
 Why?
Neoplasm Recurrence, Local
7
2023
1137
1.550
 Why?
Protein-Tyrosine Kinases
4
2021
433
1.430
 Why?
Antineoplastic Combined Chemotherapy Protocols
14
2024
1953
1.430
 Why?
Neoplasms
20
2024
2875
1.410
 Why?
Lung Neoplasms
11
2026
2637
1.390
 Why?
Anilides
6
2024
84
1.340
 Why?
Gonanes
7
2016
28
1.320
 Why?
Proto-Oncogene Proteins
6
2021
623
1.300
 Why?
Thyroid Carcinoma, Anaplastic
3
2020
36
1.250
 Why?
Cetuximab
7
2018
111
1.240
 Why?
Biomarkers, Tumor
8
2020
1313
1.210
 Why?
Adenocarcinoma
7
2024
928
1.190
 Why?
Phosphatidylinositol 3-Kinases
8
2017
380
0.810
 Why?
Pyrazoles
6
2026
509
0.790
 Why?
Mutation
13
2024
4089
0.740
 Why?
Pyrimidines
6
2026
532
0.710
 Why?
Carcinoma
3
2019
228
0.710
 Why?
Phytotherapy
2
2012
74
0.690
 Why?
Drugs, Investigational
2
2011
31
0.680
 Why?
Neoplasm Staging
15
2019
1462
0.670
 Why?
Cisplatin
6
2024
334
0.670
 Why?
Neoplasms, Second Primary
1
2021
100
0.620
 Why?
Papillomaviridae
4
2019
115
0.610
 Why?
Disease-Free Survival
10
2017
769
0.610
 Why?
Antineoplastic Agents, Immunological
2
2018
199
0.600
 Why?
Taxoids
3
2015
116
0.600
 Why?
Quinolines
5
2024
193
0.590
 Why?
Hedgehog Proteins
3
2015
197
0.590
 Why?
Carcinoma, Renal Cell
3
2017
234
0.580
 Why?
Humans
90
2026
144759
0.580
 Why?
Marijuana Smoking
2
2012
250
0.550
 Why?
Tumor Suppressor Proteins
2
2018
321
0.550
 Why?
Proto-Oncogene Proteins c-ret
5
2026
40
0.540
 Why?
Drug Resistance, Neoplasm
8
2024
881
0.540
 Why?
Middle Aged
44
2026
35875
0.520
 Why?
Kidney Neoplasms
3
2017
412
0.510
 Why?
Carcinoma, Mucoepidermoid
1
2017
17
0.510
 Why?
Colorectal Neoplasms
2
2016
845
0.510
 Why?
Aged
40
2026
25913
0.500
 Why?
Carcinoma, Transitional Cell
4
2017
68
0.500
 Why?
Ubiquitin Thiolesterase
1
2017
68
0.500
 Why?
Carcinoma, Ductal
1
2016
10
0.490
 Why?
Adenoma, Pleomorphic
1
2016
9
0.490
 Why?
Sulfones
2
2014
127
0.480
 Why?
Gene Rearrangement
2
2018
155
0.480
 Why?
Cannabinoids
2
2024
182
0.470
 Why?
Glycine
2
2014
187
0.470
 Why?
Maximum Tolerated Dose
5
2017
212
0.440
 Why?
Melanoma
1
2021
761
0.420
 Why?
Drug Interactions
6
2017
398
0.410
 Why?
Enzyme Inhibitors
3
2014
824
0.410
 Why?
Pyrroles
1
2014
217
0.400
 Why?
Iodine Radioisotopes
5
2024
136
0.390
 Why?
Gene Fusion
3
2023
29
0.390
 Why?
Signal Transduction
8
2018
5226
0.390
 Why?
Phenylurea Compounds
4
2024
112
0.390
 Why?
Receptor Protein-Tyrosine Kinases
2
2012
230
0.380
 Why?
Male
45
2026
72315
0.380
 Why?
Genetic Variation
1
2018
983
0.380
 Why?
Lymph Nodes
4
2017
502
0.370
 Why?
Indazoles
3
2019
80
0.370
 Why?
Aged, 80 and over
16
2026
8265
0.370
 Why?
Female
46
2026
78271
0.360
 Why?
Quinazolines
1
2013
266
0.350
 Why?
Class I Phosphatidylinositol 3-Kinases
4
2017
108
0.350
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2012
127
0.340
 Why?
Treatment Outcome
15
2024
11679
0.340
 Why?
Antibodies, Monoclonal, Humanized
4
2024
985
0.330
 Why?
Neoplasm Metastasis
6
2021
688
0.320
 Why?
Adult
27
2026
40449
0.300
 Why?
Prognosis
9
2021
4282
0.280
 Why?
ErbB Receptors
4
2017
627
0.280
 Why?
Benzamides
3
2022
224
0.270
 Why?
Pharmacogenomic Variants
2
2018
33
0.270
 Why?
Papillomavirus Infections
3
2022
345
0.260
 Why?
Urologic Neoplasms
2
2017
31
0.250
 Why?
Nitriles
2
2022
205
0.250
 Why?
Carcinoma, Ductal, Breast
1
2007
88
0.250
 Why?
Mitoxantrone
1
2006
15
0.250
 Why?
Platinum
2
2024
50
0.250
 Why?
Xenograft Model Antitumor Assays
7
2024
928
0.240
 Why?
Enterobacter
1
2006
9
0.240
 Why?
Tooth Diseases
1
2006
13
0.240
 Why?
Esophageal and Gastric Varices
1
2006
36
0.240
 Why?
Enterobacteriaceae Infections
1
2006
41
0.230
 Why?
Gene Expression Profiling
5
2018
1782
0.230
 Why?
Salivary Glands
2
2023
36
0.230
 Why?
Oropharyngeal Neoplasms
2
2016
55
0.230
 Why?
Acute Kidney Injury
3
2018
865
0.230
 Why?
Animals
16
2024
38058
0.220
 Why?
Serotonin 5-HT3 Receptor Antagonists
1
2024
5
0.220
 Why?
Chemoradiotherapy
4
2020
237
0.220
 Why?
Proto-Oncogene Proteins B-raf
2
2024
225
0.220
 Why?
Clinical Trials as Topic
3
2018
1053
0.220
 Why?
Cannabis
1
2011
509
0.210
 Why?
Antiemetics
1
2024
49
0.210
 Why?
Receptors, Estrogen
1
2007
457
0.210
 Why?
Immunotherapy
2
2023
653
0.210
 Why?
Oncogene Proteins, Fusion
1
2026
210
0.210
 Why?
Urinary Bladder Neoplasms
2
2017
255
0.210
 Why?
Registries
2
2016
2385
0.200
 Why?
Liver Cirrhosis
1
2006
288
0.200
 Why?
Carcinoma, Adenoid Cystic
1
2023
19
0.200
 Why?
Combined Modality Therapy
4
2018
1266
0.200
 Why?
Bacteremia
1
2006
221
0.200
 Why?
Gene Expression Regulation, Neoplastic
3
2019
1455
0.200
 Why?
Models, Biological
3
2024
1821
0.200
 Why?
Administration, Oral
3
2014
847
0.190
 Why?
Phenylthiohydantoin
1
2022
44
0.180
 Why?
Medical Marijuana
1
2024
123
0.180
 Why?
Survival Rate
5
2021
2089
0.180
 Why?
Radiation Pneumonitis
1
2021
31
0.170
 Why?
Drug Evaluation, Preclinical
2
2013
194
0.170
 Why?
Chemotherapy, Adjuvant
3
2017
421
0.170
 Why?
Survival Analysis
4
2020
1382
0.170
 Why?
Referral and Consultation
1
2007
851
0.170
 Why?
Carcinoma, Neuroendocrine
1
2021
35
0.170
 Why?
Disease Susceptibility
2
2020
348
0.160
 Why?
Adrenal Cortex Neoplasms
1
2021
65
0.160
 Why?
Adrenocortical Carcinoma
1
2021
67
0.160
 Why?
TOR Serine-Threonine Kinases
2
2016
449
0.160
 Why?
Gene Expression
2
2015
1490
0.160
 Why?
Cystectomy
2
2017
41
0.160
 Why?
SEER Program
1
2021
224
0.160
 Why?
Receptors, Nerve Growth Factor
1
2019
18
0.150
 Why?
Kaplan-Meier Estimate
3
2017
965
0.150
 Why?
DNA Mutational Analysis
2
2018
406
0.150
 Why?
Leukemia, Myeloid, Acute
1
2006
682
0.150
 Why?
Lymph Node Excision
2
2017
173
0.150
 Why?
Tracheal Neoplasms
1
2019
12
0.150
 Why?
Prostatic Neoplasms
1
2006
974
0.150
 Why?
United States
8
2021
15966
0.140
 Why?
Smad4 Protein
1
2019
34
0.140
 Why?
Positron Emission Tomography Computed Tomography
1
2020
117
0.140
 Why?
Alphapapillomavirus
2
2016
35
0.140
 Why?
Benzazepines
1
2018
35
0.140
 Why?
Radiosurgery
1
2022
400
0.140
 Why?
Genetic Heterogeneity
1
2019
62
0.140
 Why?
Risk
1
2021
911
0.140
 Why?
Disease Management
2
2020
645
0.140
 Why?
Genomics
3
2021
834
0.140
 Why?
Chromosome Aberrations
1
2019
162
0.140
 Why?
DNA Mismatch Repair
1
2018
52
0.140
 Why?
Tissue Fixation
1
2017
36
0.130
 Why?
Paraffin Embedding
1
2017
32
0.130
 Why?
Smokers
1
2018
137
0.130
 Why?
Oncogenes
1
2018
119
0.130
 Why?
Erlotinib Hydrochloride
1
2017
72
0.130
 Why?
Formaldehyde
1
2017
66
0.130
 Why?
Nasopharyngeal Neoplasms
1
2017
20
0.130
 Why?
Gene Deletion
1
2019
389
0.130
 Why?
Radiotherapy, Intensity-Modulated
1
2018
141
0.130
 Why?
DNA, Neoplasm
1
2017
163
0.130
 Why?
Neoplasm Grading
1
2018
307
0.130
 Why?
Health Services Needs and Demand
1
2019
280
0.130
 Why?
Gene Frequency
1
2018
481
0.120
 Why?
Chemoradiotherapy, Adjuvant
1
2016
44
0.120
 Why?
Induction Chemotherapy
1
2017
87
0.120
 Why?
Salivary Ducts
1
2016
2
0.120
 Why?
Palliative Care
2
2018
1002
0.120
 Why?
Laryngeal Neoplasms
1
2016
35
0.120
 Why?
Muscle, Smooth
1
2017
153
0.120
 Why?
Carboplatin
1
2016
160
0.120
 Why?
Nomograms
1
2016
59
0.120
 Why?
Patient Navigation
1
2018
104
0.120
 Why?
Database Management Systems
1
2016
50
0.120
 Why?
Dose-Response Relationship, Drug
3
2017
2027
0.120
 Why?
Hospice and Palliative Care Nursing
1
2018
113
0.120
 Why?
Prospective Studies
7
2024
7990
0.120
 Why?
Disease Progression
4
2018
2847
0.120
 Why?
Population Surveillance
1
2019
485
0.110
 Why?
Young Adult
5
2021
14105
0.110
 Why?
Computational Biology
2
2018
680
0.110
 Why?
Angiopoietin-1
1
2015
12
0.110
 Why?
Angiopoietin-2
1
2015
15
0.110
 Why?
Incidence
2
2019
2879
0.110
 Why?
Radiotherapy
1
2016
206
0.110
 Why?
Bone Neoplasms
1
2017
253
0.110
 Why?
Genetic Testing
1
2018
478
0.110
 Why?
Zinc Finger Protein GLI1
1
2014
26
0.110
 Why?
Retrospective Studies
8
2021
17066
0.110
 Why?
Retreatment
1
2014
77
0.110
 Why?
Hospice Care
1
2018
218
0.110
 Why?
Response Evaluation Criteria in Solid Tumors
1
2014
21
0.110
 Why?
Breast Neoplasms
1
2007
2452
0.110
 Why?
Neoplasms, Unknown Primary
1
2014
20
0.110
 Why?
Piperazines
2
2018
381
0.110
 Why?
Proto-Oncogene Proteins c-akt
1
2016
436
0.100
 Why?
Neoplastic Stem Cells
1
2018
412
0.100
 Why?
Paclitaxel
1
2015
255
0.100
 Why?
High-Throughput Nucleotide Sequencing
1
2017
549
0.100
 Why?
Patient Satisfaction
1
2018
704
0.100
 Why?
Veratrum Alkaloids
1
2013
20
0.100
 Why?
Sulfonamides
1
2017
580
0.100
 Why?
ras Proteins
1
2014
150
0.100
 Why?
Promoter Regions, Genetic
1
2018
1257
0.100
 Why?
Proportional Hazards Models
4
2017
1325
0.100
 Why?
Proto-Oncogene Proteins p21(ras)
1
2014
253
0.100
 Why?
PTEN Phosphohydrolase
1
2014
164
0.100
 Why?
Cell Cycle Proteins
2
2014
628
0.090
 Why?
Pilot Projects
2
2015
1886
0.090
 Why?
Imatinib Mesylate
1
2012
77
0.090
 Why?
Dasatinib
1
2012
57
0.090
 Why?
Recombinant Fusion Proteins
1
2015
675
0.090
 Why?
Risk Assessment
2
2019
3671
0.090
 Why?
Thiazoles
1
2012
135
0.090
 Why?
Smoking
1
2019
1472
0.090
 Why?
Aniline Compounds
1
2012
119
0.090
 Why?
Hematopoietic Stem Cells
1
2015
420
0.090
 Why?
Biomarkers
3
2018
4271
0.090
 Why?
Proto-Oncogene Proteins c-met
1
2012
75
0.090
 Why?
Biological Availability
1
2011
142
0.090
 Why?
Evidence-Based Medicine
2
2012
732
0.090
 Why?
Phosphatidylinositol 3-Kinase
1
2011
25
0.080
 Why?
Imidazoles
1
2012
254
0.080
 Why?
Mice
7
2024
18339
0.080
 Why?
Vascular Endothelial Growth Factor A
2
2024
557
0.080
 Why?
Adolescent
5
2022
22428
0.080
 Why?
Propensity Score
3
2017
367
0.080
 Why?
Tumor Microenvironment
1
2015
732
0.080
 Why?
Cell Line, Tumor
4
2024
3540
0.080
 Why?
Phenotype
1
2018
3162
0.080
 Why?
Algorithms
1
2018
1837
0.080
 Why?
Genetic Predisposition to Disease
1
2018
2363
0.080
 Why?
Kidney
1
2017
1495
0.070
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2024
109
0.070
 Why?
Multivariate Analysis
3
2017
1539
0.070
 Why?
Adaptation, Psychological
1
2014
717
0.070
 Why?
Brain Neoplasms
1
2018
1318
0.070
 Why?
Axilla
1
2007
51
0.070
 Why?
Clinical Trials, Phase I as Topic
2
2019
52
0.060
 Why?
Cohort Studies
4
2022
5960
0.060
 Why?
Neoadjuvant Therapy
2
2022
462
0.060
 Why?
Sentinel Lymph Node Biopsy
1
2007
118
0.060
 Why?
RNA, Messenger
1
2014
2832
0.060
 Why?
Transcription Factors
1
2014
1741
0.060
 Why?
Mastectomy
1
2007
162
0.060
 Why?
Ligation
1
2006
92
0.060
 Why?
Pain
1
2011
779
0.060
 Why?
Stress, Psychological
1
2014
1152
0.060
 Why?
Creatinine
2
2018
506
0.060
 Why?
Fatal Outcome
1
2006
307
0.060
 Why?
Caregivers
1
2014
1049
0.060
 Why?
Lymphatic Metastasis
2
2017
333
0.060
 Why?
Neoplasm Invasiveness
2
2017
508
0.060
 Why?
Receptors, Progesterone
1
2007
356
0.060
 Why?
Granisetron
1
2024
6
0.060
 Why?
Quinuclidines
1
2024
11
0.060
 Why?
Ondansetron
1
2024
19
0.060
 Why?
Double-Blind Method
2
2021
2029
0.060
 Why?
Gastrointestinal Hemorrhage
1
2006
136
0.050
 Why?
Isoquinolines
1
2024
44
0.050
 Why?
Skin Neoplasms
1
2012
847
0.050
 Why?
Risk Factors
1
2019
10779
0.050
 Why?
Neoplasm Proteins
1
2007
442
0.050
 Why?
Glomerular Filtration Rate
2
2018
760
0.050
 Why?
Demography
2
2015
288
0.050
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2023
85
0.050
 Why?
Benzimidazoles
1
2024
190
0.050
 Why?
Recurrence
2
2018
1135
0.050
 Why?
Databases, Factual
2
2019
1486
0.040
 Why?
Four-Dimensional Computed Tomography
1
2021
38
0.040
 Why?
Androgen Antagonists
1
2022
91
0.040
 Why?
Immunohistochemistry
2
2018
1716
0.040
 Why?
Pulmonary Ventilation
1
2021
83
0.040
 Why?
Receptors, Androgen
1
2022
153
0.040
 Why?
Quality of Life
1
2013
3185
0.040
 Why?
Radiotherapy Planning, Computer-Assisted
1
2021
149
0.040
 Why?
Receptor, trkA
1
2019
15
0.040
 Why?
Receptor, trkC
1
2019
10
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
77
0.040
 Why?
Receptor, trkB
1
2019
36
0.040
 Why?
Trastuzumab
1
2019
118
0.040
 Why?
Extracellular Signal-Regulated MAP Kinases
1
2020
173
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
39
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2019
322
0.030
 Why?
Phthalazines
1
2018
64
0.030
 Why?
Organic Cation Transporter 2
1
2017
8
0.030
 Why?
Glutathione S-Transferase pi
1
2017
10
0.030
 Why?
Retroperitoneal Space
1
2017
18
0.030
 Why?
Organic Cation Transport Proteins
1
2017
25
0.030
 Why?
Urinary Diversion
1
2017
13
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
52
0.030
 Why?
Tumor Cells, Cultured
1
2019
919
0.030
 Why?
Membrane Glycoproteins
1
2019
496
0.030
 Why?
Social Work
1
2018
85
0.030
 Why?
Margins of Excision
1
2017
51
0.030
 Why?
Immunophenotyping
1
2018
322
0.030
 Why?
Laryngectomy
1
2016
16
0.030
 Why?
Hospitals, Veterans
1
2018
259
0.030
 Why?
Kidney Function Tests
1
2017
157
0.030
 Why?
Oncologists
1
2017
46
0.030
 Why?
Cation Transport Proteins
1
2017
118
0.030
 Why?
Viral Core Proteins
1
2016
22
0.030
 Why?
Pelvis
1
2017
124
0.030
 Why?
Carcinogenesis
1
2018
229
0.030
 Why?
Regression Analysis
1
2018
1003
0.030
 Why?
Heart
1
2020
636
0.030
 Why?
Radiotherapy, Adjuvant
1
2016
222
0.030
 Why?
Disease Models, Animal
2
2018
4557
0.030
 Why?
Internationality
1
2016
156
0.030
 Why?
Random Allocation
1
2016
363
0.030
 Why?
Anti-Bacterial Agents
1
2006
1907
0.030
 Why?
Antibodies, Neoplasm
1
2015
34
0.030
 Why?
Antibodies, Monoclonal
1
2022
1519
0.030
 Why?
Biopsy, Large-Core Needle
1
2014
15
0.030
 Why?
Myocardium
1
2020
939
0.030
 Why?
Robotic Surgical Procedures
1
2017
182
0.030
 Why?
Analysis of Variance
1
2017
1306
0.030
 Why?
Bone Marrow
1
2015
304
0.020
 Why?
Receptor, Notch2
1
2013
15
0.020
 Why?
Receptor Cross-Talk
1
2013
21
0.020
 Why?
Receptor, Notch1
1
2013
64
0.020
 Why?
Metabolic Clearance Rate
1
2012
114
0.020
 Why?
Psychiatric Status Rating Scales
1
2014
541
0.020
 Why?
Pandemics
1
2021
1694
0.020
 Why?
Gene Silencing
1
2013
205
0.020
 Why?
Nausea
1
2012
111
0.020
 Why?
Logistic Models
1
2017
2117
0.020
 Why?
Transcriptome
1
2018
1045
0.020
 Why?
Vomiting
1
2012
130
0.020
 Why?
Area Under Curve
1
2012
330
0.020
 Why?
Needs Assessment
1
2014
404
0.020
 Why?
Mice, Nude
1
2013
682
0.020
 Why?
Diarrhea
1
2012
192
0.020
 Why?
Blotting, Western
1
2013
1187
0.020
 Why?
Drug Administration Schedule
1
2012
779
0.020
 Why?
Cell Proliferation
1
2017
2496
0.020
 Why?
Fatigue
1
2012
366
0.020
 Why?
Time Factors
1
2019
7173
0.020
 Why?
Age Factors
1
2016
3333
0.020
 Why?
Lung
1
2021
4109
0.020
 Why?
Colorado
1
2018
4564
0.020
 Why?
Cytokines
1
2015
2061
0.020
 Why?
Follow-Up Studies
1
2016
5408
0.020
 Why?
Surveys and Questionnaires
1
2018
6048
0.010
 Why?
Cross-Sectional Studies
1
2014
5868
0.010
 Why?
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (346) concept(s)
_
Co-Authors Expand Description
See all (69) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)